Anti-CSPG4 antibodies induced by the vaccination directly down-regulate CSPG4 expression in-vitro hampering CSPG4 tumorigenic functions in melanoma cells, suggesting that they could have a beneficial impact on the clinical course of the disease (9, 19, 82). The gene discussed is CSPG4; the disease is melanoma.